바카라사이트 추천 1b data for the nelmastobart and BTN1A1 biomarker study presented at the ASCO GI Symposium
[by Jin, Yu Jeong] STCube announced on January 12 that it presented ‘Translational Study Data for Predicting and Confirming the Efficacy of a BTN1A1-Targeted Treatment Strategy in Colorectal Cancer’ at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2026). The meeting was held in San Francisco, California, from January 8 to 10 (local time).
One abstract focusing on the BTN1A1-targeting antibody ‘nelmastobart’ was accepted for presentation at the conference. An analysis of phase 1b clinical trial data, incorporating immunohistochemical staining of colorectal cancer patient tissue samples, demonstrated a correlation between the co-expression of BTN1A1 and nuclear YAP1 and the observed clinical efficacy of nelmastobart.
The study was presented under the abstract title, ‘BTN1A1 Expression as a Biomarker for Patient Selection: Phase 1b IHC Analysis and Clinical Outcomes Supporting a Biomarker-Guided Phase 2 Trial in Colorectal Cancer.’
The research team had previously demonstrated in a Phase 1 clinical 바카라사이트 추천 that the expression of BTN1A1, along with several candidate biomarkers, was associated with the therapeutic efficacy of nelmastobart. Building on these findings, they conducted immunohistochemical staining and multiplex immunofluorescence analyses on tumor tissue samples obtained from six patients enrolled in a Phase 1b clinical 바카라사이트 추천 for colorectal cancer. The analyses aimed to assess whether responses to nelmastobart correlated with the proportion of cells expressing BTN1A1 and selected candidate biomarkers (Ki-67, YAP1, SLFN11, and CK).
In the Phase 1b clinical 바카라사이트 추천, two patients achieved a partial response (PR), while four patients demonstrated stable disease (SD). These patient groups demonstrated a positive correlation between BTN1A1 expression and treatment responsiveness. In addition, immunofluorescence analysis showed that the median proportion of nuclear YAP1-expressing tumor cells among BTN1A1-positive cells was 49.89%. Clinical benefit was found to be particularly high in patients who were positive for both biomarkers.
"In the Phase 1b clinical trial for colorectal cancer, two patients who exhibited a relatively higher proportion of YAP1-expressing cells within the BTN1A1-positive cell population achieved a PR. These findings further support the robustness and reliability of our ongoing precision medicine-driven clinical development strategy," said Stephen Sunghan Yoo, Chief Scientific Officer (CSO).
"Through our research, we have confirmed that multiple biomarker candidates, including BTN1A1 and YAP1, have the potential to function as predictive biomarkers in colorectal and lung cancers. Based on this, we are developing a refined predictive model and are optimizing our 2 clinical trial development strategy, thereby further strengthening the development potential of nelmastobart," Yoo further commented.
Conversely, STCube is currently conducting Phase 2 clinical 바카라사이트 추천s in metastatic colorectal cancer and non-small cell lung cancer, focusing on patients with positive BTN1A1 expression. Following its presentation at the ASCO GI 2026, the company plans to participate in the JP Morgan Healthcare Conference, where it intends to engage in discussion regarding the global technology transfer of nelmastobart.